These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 9478946)

  • 21. The pituitary adenylate cyclase activating polypeptide (PACAP I) and VIP (PACAP II VIP1) receptors stimulate inositol phosphate synthesis in transfected CHO cells through interaction with different G proteins.
    Van Rampelbergh J; Poloczek P; Françoys I; Delporte C; Winand J; Robberecht P; Waelbroeck M
    Biochim Biophys Acta; 1997 Jun; 1357(2):249-55. PubMed ID: 9223629
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human VPAC1 receptor selectivity filter. Identification of a critical domain for restricting secretin binding.
    Du K; Couvineau A; Rouyer-Fessard C; Nicole P; Laburthe M
    J Biol Chem; 2002 Oct; 277(40):37016-22. PubMed ID: 12133828
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stable expression of the recombinant human VIP1 receptor in clonal Chinese hamster ovary cells: pharmacological, functional and molecular properties.
    Gaudin P; Couvineau A; Maoret JJ; Rouyer-Fessard C; Laburthe M
    Eur J Pharmacol; 1996 Apr; 302(1-3):207-14. PubMed ID: 8791009
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The human VPAC1 receptor: three-dimensional model and mutagenesis of the N-terminal domain.
    Lins L; Couvineau A; Rouyer-Fessard C; Nicole P; Maoret JJ; Benhamed M; Brasseur R; Thomas A; Laburthe M
    J Biol Chem; 2001 Mar; 276(13):10153-60. PubMed ID: 11124960
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Construction of chimeras between human VIP1 and secretin receptors: identification of receptor domains involved in selectivity towards VIP, secretin, and PACAP.
    Du K; Nicole P; Couvineau A; Laburthe M
    Ann N Y Acad Sci; 1998 Dec; 865():386-9. PubMed ID: 9928035
    [No Abstract]   [Full Text] [Related]  

  • 26. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.
    Akesson L; Ahrén B; Edgren G; Degerman E
    Endocrinology; 2005 Feb; 146(2):744-50. PubMed ID: 15514088
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Properties of the pituitary adenylate cyclase-activating polypeptide I and II receptors, vasoactive intestinal peptide1, and chimeric amino-terminal pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide1 receptors: evidence for multiple receptor states.
    Van Rampelbergh J; Gourlet P; De Neef P; Robberecht P; Waelbroeck M
    Mol Pharmacol; 1996 Dec; 50(6):1596-604. PubMed ID: 8967982
    [TBL] [Abstract][Full Text] [Related]  

  • 28. VIP activates G(s) and G(i3) in rat alveolar macrophages and G(s) in HEK293 cells transfected with the human VPAC(1) receptor.
    Shreeve SM; Sreedharan SP; Hacker MP; Gannon DE; Morgan MJ
    Biochem Biophys Res Commun; 2000 Jun; 272(3):922-8. PubMed ID: 10860852
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vasoactive intestinal peptide (VIP) inhibits human renal cell carcinoma proliferation.
    Vacas E; Fernández-Martínez AB; Bajo AM; Sánchez-Chapado M; Schally AV; Prieto JC; Carmena MJ
    Biochim Biophys Acta; 2012 Oct; 1823(10):1676-85. PubMed ID: 22728770
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human intestinal VIP receptor: cloning and functional expression of two cDNA encoding proteins with different N-terminal domains.
    Couvineau A; Rouyer-Fessard C; Darmoul D; Maoret JJ; Carrero I; Ogier-Denis E; Laburthe M
    Biochem Biophys Res Commun; 1994 Apr; 200(2):769-76. PubMed ID: 8179610
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Importance of conserved cysteines in the extracellular loops of human PACAP/VIP1 receptor for ligand binding and stimulation of cAMP production.
    Knudsen SM; Tams JW; Wulff BS; Fahrenkrug J
    Ann N Y Acad Sci; 1998 Dec; 865():259-65. PubMed ID: 9928020
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Different vasoactive intestinal polypeptide receptor domains are involved in the selective recognition of two VPAC(2)-selective ligands.
    Juarranz MG; Van Rampelbergh J; Gourlet P; De Neef P; Cnudde J; Robberecht P; Waelbroeck M
    Mol Pharmacol; 1999 Dec; 56(6):1280-7. PubMed ID: 10570056
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular cloning and functional characterization of a human liver vasoactive intestinal peptide receptor.
    Gagnon AW; Aiyar N; Elshourbagy NA
    Cell Signal; 1994 Mar; 6(3):321-33. PubMed ID: 7917790
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analogues of VIP, helodermin, and PACAP discriminate between rat and human VIP1 and VIP2 receptors.
    Gourlet P; Vandermeers A; Van Rampelbergh J; De Neef P; Cnudde J; Waelbroeck M; Robberecht P
    Ann N Y Acad Sci; 1998 Dec; 865():247-52. PubMed ID: 9928018
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vasoactive intestinal polypeptide VPAC1 and VPAC2 receptor chimeras identify domains responsible for the specificity of ligand binding and activation.
    Juarranz MG; Van Rampelbergh J; Gourlet P; De Neef P; Cnudde J; Robberecht P; Waelbroeck M
    Eur J Biochem; 1999 Oct; 265(1):449-56. PubMed ID: 10491203
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutational analysis of the human vasoactive intestinal peptide receptor subtype VPAC(2): role of basic residues in the second transmembrane helix.
    Vertongen P; Solano RM; Perret J; Langer I; Robberecht P; Waelbroeck M
    Br J Pharmacol; 2001 Aug; 133(8):1249-54. PubMed ID: 11498510
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Highly conserved aspartate 68, tryptophane 73 and glycine 109 in the N-terminal extracellular domain of the human VIP receptor are essential for its ability to bind VIP.
    Couvineau A; Gaudin P; Maoret JJ; Rouyer-Fessard C; Nicole P; Laburthe M
    Biochem Biophys Res Commun; 1995 Jan; 206(1):246-52. PubMed ID: 7818527
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of key residues for interaction of vasoactive intestinal peptide with human VPAC1 and VPAC2 receptors and development of a highly selective VPAC1 receptor agonist. Alanine scanning and molecular modeling of the peptide.
    Nicole P; Lins L; Rouyer-Fessard C; Drouot C; Fulcrand P; Thomas A; Couvineau A; Martinez J; Brasseur R; Laburthe M
    J Biol Chem; 2000 Aug; 275(31):24003-12. PubMed ID: 10801840
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Peptidergic activation of transcription and secretion in chromaffin cells. Cis and trans signaling determinants of pituitary adenylyl cyclase-activating polypeptide (PACAP).
    Taupenot L; Mahata SK; Wu H; O'Connor DT
    J Clin Invest; 1998 Feb; 101(4):863-76. PubMed ID: 9466982
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Photoaffinity labeling demonstrates physical contact between vasoactive intestinal peptide and the N-terminal ectodomain of the human VPAC1 receptor.
    Tan YV; Couvineau A; Van Rampelbergh J; Laburthe M
    J Biol Chem; 2003 Sep; 278(38):36531-6. PubMed ID: 12807902
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.